Vimarsana
Biggest News Aggregation in the World

Sameem Abedin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sameem Abedin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sameem Abedin Today - Breaking & Trending Today

Hematologists Dive into the Current Treatment Landscape - Vimarsana News

Hematologists Dive into the Current Treatment Landscape

Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.

Wisconsin man receives life-saving transplant from England woman - Vimarsana News

Wisconsin man receives life-saving transplant from England woman

The 79-year-old man was diagnosed with rare, aggressive form of cancer

Source: wisn.com
Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML - Vimarsana News

Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML

Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Obe-cel May Prove a Tolerable Treatment Alternative in Relapsed/Refractory B-ALL - Vimarsana News

Obe-cel May Prove a Tolerable Treatment Alternative in Relapsed/Refractory B-ALL

Sameem Abedin, MD, discusses where CAR T-cell therapy falls in the treatment paradigm for B-cell acute lymphoblastic leukemia, the known safety profile of obe-cel as evidenced in early studies, and how findings from the FELIX trial could change the future management of this disease.

Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial - Vimarsana News

Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today...